Three Indian companies, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories and Lupin Limited, have received approval from US FDA for the first generic versions of Depakote delayed-release tablets (divalproex sodium). 

Depakote is approved by the US FDA for the treatment of seizures, bipolar disorder and migraine headaches. Generic divalproex sodium will have the same safety warnings as Depakote, including a Boxed Warning that cautions about the risk of liver damage (hepatotoxicity), including fatalities, and pancreatitis, or an inflamed pancreas, including fatal cases. The Boxed Warning also highlights the risk of birth defects (teratogenicity), including neural tube defects.